AssayIndex

SWB-2410-V4278

Enclomiphene citrate · 50 mg declared · Shanghai Wibson Biotechnology Co., Ltd. · manufactured 13 Oct 2024

PARTIALLY CHARACTERISED
Lot code
SWB-2410-V4278
Supplier
SWB — Shanghai Wibson Biotechnology Co., Ltd.
Compound
Enclomiphene citrate
Compound class
Non-peptide adjuncts
Declared label claim
50mg
Manufacture date
13 Oct 2024
Index quarter
2024-Q4
Independent assays
2
Laboratories involved
Janoshik
Provenance mix
Supplier-supplied ×1 · Laboratory-retained ×1
Section 1

Reproducibility across independent tests

Every report below is an observation of the same physical material. What they disagree about is measurement; what they agree about is the lot. The size of the disagreement is compared against what the contributing laboratories' own repeatability figures predict.

Independent assays 2
Median purity 99.68% n=2
Spread (max − min) 0.08pp n=2
Standard deviation n<3 n=2
97.397.898.298.799.299.7100.1This lot (SWB-2410-V4278)This lot (SWB-2410-V4278): Q1 99.66, median 99.68, Q3 99.70, n=2n=2All Enclomiphene citrateAll Enclomiphene citrate: Q1 98.27, median 99.23, Q3 99.75, n=55n=55 Purity (% area)
Figure 1. This lot's independent purity results against the whole Enclomiphene citrate record set in the index. The vertical line is the index acceptance specification for the non-peptide adjuncts class, 98.5 % area. A narrow box on the top row against a wide box on the bottom row is the ideal reading: it means the disagreement between lots is much larger than the disagreement within this one.
Section 2

Member reports 2

Every report the index holds on this lot. Each is a page carrying its own chromatogram, mass spectrum, mass balance, provenance and caveats.

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2024-004856SWB-2410-V4278Janoshik2024-Q499.646.44106.7Laboratory-retained1FAIL
AX-2025-019824SWB-2410-V4278Janoshik2024-Q499.726.07Supplier-supplied1FAIL
Section 3

By laboratory

Where more than one laboratory assayed this lot, the difference between them is a paired observation of their relative bias — the same material, the same time window, different instruments. Those pairs are what the index's bias estimates are built from.

LaboratoryReportsPurity results (% area)MedianGradientPublished bias (pp)Bias-adjusted
Janoshik299.64, 99.7299.6830min+0.0099.68

A single laboratory assayed this lot, so it contributes no paired comparison and the bias-adjusted column is a subtraction rather than a measurement.

Section 4

The supplier's certificate for this lot

One number the supplier wrote, beside the median of the numbers other people measured on the same physical material. That comparison is only available because the index groups by lot.

FigureSupplier COAThis reportIndex note
Purity (% area)99.9099.64divergence +0.22 pp vs batch median
Total impurities (% area)0.100.36
Largest single impurity (% area)0.060.15
Water (%)5.96.44
Counter-ion (%)not stated26.87
Peptide content (%w/w)not stated66.23
Endotoxin (EU/mg)not statednot determined
Method stated on certificateYEScolumn, gradient and wavelength given
Section 5

Impurity fingerprint

The named impurities reported across this lot's assays, with how consistently each was seen. A fingerprint is what allows two lot numbers held by different companies to be identified as one bulk.

Named impurityReported inMedian % areaRange
zuclomiphene (cis-isomer)2 / 20.100.05–0.15
free base (des-citrate)2 / 20.060.02–0.10
des-ethyl enclomiphene (−28 Da)2 / 20.140.07–0.20
N-oxide (+16 Da)2 / 20.030.01–0.04
Section 7

What this rollup does not establish